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Abstract 
Nasopharyngeal carcinoma (NPC) is a unique malignant head and
neck cancer with clinical, demographic, and geographic features dis-
tinct from other head and neck epithelial malignancies. Non-keratiniz-
ing, poorly differentiated, and undifferentiated WHO types 2 and 3 is
the most common subtypes of NPC. NPC is also characterized by its
relatively high sensitivity to radiation, so that in the last decades
radiotherapy (RT) has been the cornerstone of treatment. However, in
the majority of cases NPC is discovered at locally advanced stage. The
results are disappointing when RT alone is offered. The 5-year survival
rates have been reported to be about 34-52%. The poor prognosis for
advanced NPC led to increasing interests in exploring the use of
chemotherapy (CT). NPC has been considered to be not only radiosen-
sitive but also chemo-sensitive and has shown high response rate to
various chemotherapeutic agents. Certainly, the treatment strategies
for NPC will continue to change and evolve as a better understanding
is gained of the molecular and immune mechanisms that drive this
disease. We reviewed the current literature focusing on the role of CT
and new-targeted agents.
Introduction
Nasopharyngeal carcinoma (NPC) is a unique malignant head/neck
cancer with clinical, demographic, and geographic features distinct
from other head and neck epithelial malignancies. First, NPC patients
are usually younger than patients with squamous cell head and neck
cancers. Secondarily, there are geographic regions in the world where
NPC is endemic, such as in Southeast Asia, or Northern Africa, and
parts of the Mediterranean basin.1
According to the global registry of cancer incidence, NPC ranked
11th among all malignancies in China in 2008, with an incidence rate
of 2.8/100,000 person years in men and 1.9/100,000 person years in
women.2 Non-keratinizing, poorly differentiated, and undifferentiated
[World Health Organization (WHO) types 2 and 3] is the most com-
mon subtypes of NPC.3 Outside of these specific areas, the incidence
of NPC remains very low, especially in Western Europe or in the United
States; in these countries, the main histological version is the differ-
entiated type that is related to tobacco use (incidence 0.5-2/100,000
people per year). On the whole, keratinizing differentiated carcinoma
has a reputation for less consistent primary tumor response to thera-
pies compared with the undifferentiated subtypes, which on the other
hand carry a higher risk of distant metastases and tend to have a more
aggressive biological behavior.
NPC WHO type 2-3 differ from WHO type 1 with regard to their
heightened sensitivity to chemotherapy (CT) and to the association
with the Epstein-Barr virus (EBV) in more than 90% of cases.2 The
relationship with EBV is of interest not only for epidemiological rea-
sons or diagnosis, but also for the monitoring of patients, prognosis
and therapeutic strategies.4-6
NPC is also characterized by its relatively high sensitivity to radia-
tion, so that in the last decades radiotherapy (RT) has been the corner-
stone of treatment. Patients presenting with early-stage disease (T1-
2a; N0; M0) are a minority and may be effectively treated with exclu-
sive RT. However, in the majority of cases NPC is discovered at locally
advanced stage. The results are disappointing when RT alone is
offered. The 5-year survival rates have been reported to be about 34-
52%.7-14 The poor prognosis for advanced NPC led to increasing inter-
ests in exploring the use of CT. NPC has been considered to be not only
radiosensitive but also chemo-sensitive and has shown high response
rate to various chemotherapeutic agents.15-18
The integration of CT with standard RT in the treatment of patients
with non-metastatic Stage III/IV NPC is based on the following ration-
ale/hypotheses: i) to minimize the risk of distant recurrence through
eradication of micro-metastases; ii) to enhance the effects of radiation
through synergistic agents (radio-sensitizers); iii) to facilitate plan-
ning of RT and to improve local disease control by reducing the tumor
volume prior to irradiation.
Concurrent–adjuvant chemo-therapy for locallyadvanced nasopharyngeal carcinoma
Today CT is usually integrated into the RT approach for most
patients with non-metastatic Stage III/IV NPC. In particular, since the
publication of the results of the Intergroup Study 0099,19 concomitant
chemo-radiotherapy (CRT) and adjuvant CT has been widely accepted
as standard in the treatment of patients with stage III and IV NPC. The
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Intergroup-0099 trial (INT-0099) is the first phase III randomized trial
comparing CRT versus exclusive RT in patients with locally advanced
NPC. It was coordinated by the Southwest Oncology Group (SWOG),
with the participation of Radiation Therapy Oncology Group (RTOG)
and Eastern Cooperative Oncology Group (ECOG). The patients were
stratified by tumor stage, nodal stage, performance status, and histol-
ogy into CRT arm or RT arm. 
RT was administered in both arms: 1.8-2.0 Gy per fraction was deliv-
ered for 35-39 fractions to a total dose of 70 Gy. Patients in the CRT arm
received cisplatin 100 mg/m2 on days 1, 22, and 43 during RT, followed
by adjuvant cisplatin 80 mg/m2 on day 1 and 5-fluorouracil 1000 mg/m2
on days 1-4, every 4 weeks, for three cycles. The study found a highly
significant 3-year overall survival (OS) advantage for the CRT arm
(76% vs 46%, P<0.001). In the updated report,20 the 5-year results con-
tinued to show a statistically significant difference in OS: 67% in the
CRT arm, compared with 37% in the RT arm (P=0.001). In addition,
improved disease-free survival (DFS) and decreased both loco-regional
failure and distant metastasis occurrence were also observed in the
CRT arm. However, the reproducibility of the Intergroup findings and,
more specifically, the benefit of its experimental regimen in regions of
endemic NPC were questioned.2,21 Many Asian institutions initiated
similar phase III studies to evaluate the role of concurrent CRT in NPC
in their patient populations.22-26 In 2002, Chan et al.22 from Hong Kong
were the first Asian group to publish the results of their concurrent
CRT study, and, in their initial publication, no improvement was found
in 2-year progression-free survival (PFS) with the addition of weekly
cisplatin (40 mg/m2) administered concurrently with conventional RT.
In a recent update,27 however, the Authors reported the concurrent CRT
arm to be associated with improvements in both 5-year PFS and OS. In
addition, Lin et al.23 from Taiwan, Kwong et al.24 from Hong Kong, Wee
et al.25 from Singapore, Lee et al.28,29 from Hong Kong and Chen et al.
from Guangzhou,30 have recently published or reported in abstract form
the results of their trials. In particular the results of the latter three tri-
als not only confirmed the findings of the 00-99 study, but also showed
a different gain in survival. The absolute increase in 5-year OS ranged
from 40% in the Intergroup-0099 Study19 to 18% by Wee,25 10% by
Chen30 and 4% in Lee.29 One major question regarding the design of
the Intergroup-0099 regimen19 is the contribution of the adjuvant
phase, because the available randomized trials24,31,32 and two recent
meta-analysis33,34 showed that adjuvant CT per se had no statistically
significant impact for all endpoints. 
To our knowledge, no randomized trial to date has compared the effi-
cacy of CRT versus CT alone. The only available data are from a retro-
spective comparison by Cheng et al.,35 who showed that inclusion of the
adjuvant phase was beneficial for patients with intermediate risk (T2b-
3N0-2M0); in this study, the 5-year OS by concurrent-adjuvant CT was
84%, compared with 63% for RT or concurrent CRT alone (P=0.005).
Controversy continues about the optimal schedule and the duration of
CT, including the types of drugs and their doses.Meta-analysis
In an attempt to assess the potential benefit of adding CT to standard
RT in locally advanced NPC, some authors conducted meta-analysis.
The meta-analysis by Huncharak et al.36 reported pooled results of
six randomized trials.27,37-41 All trials compared standard radical exter-
nal beam RT (control arm) plus CT delivered either adjuvantly, neoad-
juvantly, or concurrently with RT. Pooling all six studies using DFS/PFS
as endpoints, data showed that the addition of CT to RT increased
DFS/PFS by 37% at 2 years, 40% at 3 years, and 34% at 4 years after
treatment. Three- and 4-year OS was increased by 19% and 21%,
respectively, with the data for 4-year survival being statistically signifi-
cant. The addition of CT to standard radical RT for loco-regionally
advanced NPC increases both DFS/PFS and OS by 19-40% at 2 to 4 years
after treatment, depending on the endpoint of interest. Likewise, the
summary relative risk for OS at 2 years after treatment with the addi-
tion of CT to the treatment regimen was 0.80 (0.63-1.02), reflecting a
20% increase in 2-year survival.
In an update of the analysis significant heterogeneity was identified
across trials, and the authors concluded that the trial by Al-Sarraf et al.
was the source of the heterogeneity. The authors reported that CRT sig-
nificantly improved 2-4 year DFS by approximately 35-40% over RT
alone.19,39 CRT did not improve two- and three-year OS in patients over
RT alone; however, four-year results achieved statistical significance.
We have to be aware of the distribution of WHO histologic type in the
six trials. The majority of WHO histology was type II and III in all trials
except the INT-0099 in which type I accounted for 20-30%.
Epidemiologic study have identified WHO histologic type as an inde-
pendent prognostic factor for survival in NPC.42,43
Type II and III tumors are more often controlled by RT than type I
tumor, and the 5-year OS rate is significantly better for type II and III
than type I (51% vs 6%).44 To avoid biased results potentially caused by
tumor histology, a sensitivity study performed by excluding the INT-099
from the meta-analysis and summary odds ratio (OR p) was recalculat-
ed. However, a statistically significant result with an OR p of 0.73 (95%
CI, 0.59-0.91) was found despite the omission of the INT-0099 from the
analysis, suggesting WHO type I tumors did not result in a strong
impact on outcome.36
The meta-analysis reported by Langendijk et al.33 employed the haz-
ard ratio (HR) to assess OS across 10 trials with a total of 2450
patients. Results from this analysis indicate a small but significant OS
benefit in favor of CRT when compared with RT alone. The greatest
magnitude of effect was detected for concurrent CT regimens
(HR=0.48; 95% CI, 0.32-0.72). 
The third meta-analysis,45 published as an abstract, pooled results
from 78 randomized trials (9279 patients) that were identified in
English and non-English-based databases. Results were expressed
using the odds ratio and the random effects model. Significant differ-
ences in OS and DFS were detected in favor of CRT when compared
with RT alone. When sensitivity analyses were conducted to remove
studies rated as low quality, the results remained unchanged. The
greatest magnitude of effect in OS was detected with concurrent plus
adjuvant CT (OR=0.33; 95% CI, 0.20 to 0.56), however neoadjuvant and
concurrent CT also produced significant improvements over RT alone.
When Chinese language trials were excluded in a sensitivity analysis,
the magnitude of effect associated with neoadjuvant CT became of bor-
derline significance.
The meta-analysis of CT in nasopharyngeal carcinoma study of the
MAC-NPC Collaborative Group is the only meta-analysis that used an
individual patient data design.34 As reported in 2006, the MAC-NPC
study included 8 randomized trials, which had completed accrual before
end of 2001 and thus excluded the more recent trials from Asia. In the
meta-analysis, there were 4 trials that investigate induction CT (plus
adjuvant CT in 1 trial), 3 trials that investigate concurrent CRT (plus
adjuvant CT in 2 trials) and 1 trial that investigate adjuvant CT alone.
Overall, an absolute survival benefit of 6% at 5 year from addition of CT
was observed (from 56-62%).
A significant interaction was observed between the timing of CT and
OS, with the highest benefit resulting from concurrent CRT.
More recently, Zhang et al.46 performed a first meta-analysis of con-
current CT versus RT alone in NPC treatment, which included six, ran-
domized controlled trials with 1483 patients done only in endemic
areas. Published in an abstract form, the analysis found an HR of 0.65
(95% CI, 0.51-0.83), 0.72 (95% CI, 0.59-0.87), and 0.72 (95% CI, 0.54-
0.95) in favor of CRT for 2-, 3-, and 5-year OS, respectively. In addition,
CRT was also associated with both improvement of loco-regional recur-
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rence rate and distant metastasis rate. Apparently, the study may allow
establishing concurrent CRT as standard practice for NPC patients with
locally advanced disease in endemic regions.
Concluding, the results of meta-analyses showed that concomitant
CT in addition to RT is probably the most effective way to improve OS
in NPC. Neoadjuvant CT significantly reduced the risk of loco-regional
recurrence and distant metastases; therefore, the addition of induction
CT to concomitant CRT warrants additional investigation. The exact
role of adjuvant CT remains unclear because it has not been adequate-
ly tested and the compliance is difficult.Induction chemotherapy
In the early-randomized trials, induction CT is the most often stud-
ied combination.47-49 The rationale for induction CT is to reduce tumor
load of loco-regional disease before start of RT and also early use of sys-
temic treatment for eradication of micro-metastases. The role of
neoadjuvant CT before RT or CRT is a matter of outstanding interest. 
Initially, RT alone was considered as the control arm in randomized
trials. Ma et al.39 showed the lack of significant survival benefit with
the addition of neoadjuvant CT (cisplatin, bleomycin, and 5-FU) to
standard radiation therapy in patients with loco-regionally advanced
NPC. Al-Amro et al.,50 tested induction CT (cisplatin and epirubicin)
followed by a radical course of RT with three cycles of concurrent cis-
platin in the same patient population. This study, carried out in 110
patients, showed encouraging results in terms of safety and effective-
ness. The only induction trial that showed a significant improvement of
DFS was the International Nasopharyngeal Carcinoma Study Group,40
using combination of bleomycin, epirubicin and cisplatin. However,
there was no improvement in OS. This discrepancy in findings for dis-
ease-free and OS may be due to the increased treatment-related death
among patients on induction CT which would offset the benefit of CT
in reducing disease-related death. The impressive activity of the tax-
anes, namely docetaxel and paclitaxel, against HNSCC48,49,51 sparked
new interest in induction CT also in nasopharyngeal cancer. Paclitaxel
is a compound derived from the bark of the Pacific yew, and causes cell
death by binding to beta-tubulin resulting in cell cycle arrest at G2-M
phase. Docetaxel, a semi-synthetic taxoid, has a similar mechanism of
action. The combination of paclitaxel and carboplatin was shown to
have a high response rate (75%) in patients with metastatic NPC,52 and
has demonstrated encouraging activity and safety profiles as a neoad-
juvant treatment of NPC.53 A number of uncontrolled phase II studies,
have explored neoadjuvant taxanes-based CT followed by CRT in NPC.
The results have been encouraging, and toxicity has been acceptable.
Bossi et al.53 presented the data of a study of docetaxel, cisplatin, 5-FU
as induction CT followed by concomitant cisplatin/RT. After completion
of treatment, complete response (CR) and partial response (PR) were
observed in 78 and 20% of the patients, respectively. Recently they pub-
lished the first study to evaluate TPF induction CT as a part of a
sequential regimen including IMRT concurrent with high-dose cis-
platin CT in 30 patients with locally advanced NPC.54 All patients
showed a PR after induction CT and a high rate of CR after completing
treatment (28/30; 93% of patients). At a median follow-up of 35 months
a CR was still evident in 24 (80%) patients, while 6 (20%) experienced
recurrence of disease. Three-year PFS and OS were 79% and 87%,
respectively. During CRT, neutropenia (40%) and mucositis (43%)
were the most frequent grade 3-4 adverse events. Mean dose of IMRT
was 68.8 Gy. Their results suggest that this treatment schedule has an
acceptable toxicity profile, allows for full RT delivery and has a promis-
ing efficacy. Noteworthy, the induction TPF used in this study allowed
a reduction in the doses of 5-FU when compared with the TPF devel-
oped in Europe. 
Bae et al.,55 published the results of a phase II trial on 33 patients
treated with three cycles of induction CT (TPF Docetaxel 70 mg/m2, cis-
platin 75 mg/m2 5-FU 1000 mg/m2). After induction CT, cisplatin was
given at a dose of 100 mg/m2, every 3 weeks with RT. They obtained
15.2% of CR, and 81.8% of PR. The 3-year PFS was 75.6% and the 3-year
OS was 86.1%. Neutropenia (72.7%), febrile neutropenia (9.1%), and
nausea (9.1%) were the most severe toxicities (grade 3-4) during
induction CT, and mucositis (39.4%), fatigue (15.2%), and nausea
(9.1%) were the most common toxicities (grade 3-4) during CRT.
Hui et al.56 have recently published the results of a randomized
phase II trial in which stage III to IVB NPC untreated earlier were ran-
domly assigned to receive either neoadjuvant docetaxel and cisplatin
for two cycles followed by CRT, or CRT alone. The neoadjuvant regimen
turned out to be active and well tolerated with a manageable toxicity
profile that allowed subsequent delivery of full dose CRT.
The multicentre randomized trial by the Asian-Oceanian Clinical
Oncology Association Nasopharynx Cancer Study Group,37 showed no
significant difference in DFS or OS between the two treatment arms
(3-year RFS rate: 48% in the neoadjuvant CT arm vs. 42% in the RT
arm, P=0.45; 3-year OS rate: 78% vs 71%, P=0.57). A trend of improved
relapse free survival favoring the CT arm was observed (3-year RFS
rate: 58% vs 46%, P=0.053). In the subgroup of 49 patients with bulky
neck lymph nodes, improved RFS (3-year RFS rate: 63% vs 28%,
P=0.026) and OS (3-year OS rate: 73% vs 37%, P=0.057) were observed,
favoring the CT arm.
Hareyama et al.,57 found a trend toward improved OS or DFS favor-
ing the CT arm (5-year OS rate, 60% vs 48%; 5-year DFS, 55% vs 43%),
although the difference was not significant.Molecular targeted agents 
Several molecular targets have been identified in NPC. Expression
or over-expression of epidermal growth factor receptor (EGFR), vascu-
lar endothelial growth factor (VEGF), c-KIT, and c-erbB-2 (HER2) has
been seen in NPC.58 Inhibition of EGFR is rational, as it is over-
expressed in up to 80-90% of head and neck cancers including NPC and
is associated with an adverse outcome.59-66 Examples of EGFR
inhibitors include mAbs against the extracellular domain of this recep-
tor (e.g., cetuximab and panitumumab) and receptor tyrosine kinase
inhibitors (TKIs) that target the intracellular domain (e.g., gefitinib
and erlotinib). Given that EGFR dimerizes preferentially to the human
epidermal receptor 2 (HER-2) and this heterodimer may potentiate
receptor signaling and resistance to EGFR inhibitors, molecules that
target both of these pathways, such as lapatinib, have also been inves-
tigated.67
In NPC, the use of anti-EGFR therapy has also been tested, though
not to the same extent as head and neck squamous cell carcinoma
(HNSCC). In the metastatic/recurrent (MRHNSCC) disease setting,
the use of single anti-EGFR agent has been disappointing. Two-phase
II trials68,69 have been reported to date, utilizing gefitinib, with no evi-
dence of response, while stable disease ranged from 11-19%. A phase II
trial69 in this setting consisting of combination of cetuximab and car-
boplatin, however, showed more promising results with an ORR of 12%
and with 48% of patients having stable disease. In another trial70 the
role of maintenance therapy with erlotinib after 6 cycles of platinum-
gemcitabine CT has been recently presented. In this phase II study,
erlotinib was found not to be effective as a maintenance therapy, with
the majority of patients progressed on first assessment while on
erlotinib. These results, akin to the trials of targeted therapy in RMHN-
SCC, are very difficult to gauge in terms of efficacy, largely due to the
heterogeneity of the trial population.
In the localized disease setting for NPC, there has been a phase II
trial assessing platinum-based CRT and cetuximab. Preliminary effica-
cy data from this study, which consisted of 12 evaluable patients, were
very encouraging, with CR seen in 10 and PR in the remainder of the
cohort.71 However, similar to combination of targeted therapy and
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chemo-radiation in HNSCC, there was significant toxicity reported in
this study, with up to 85% of patients experiencing grade 3 or 4 mucosi-
tis and leucopenia. There is also ample evidence demonstrating the
central role of angiogenesis in head and neck cancers. Up to 90% of
HNSCC and NPC express angiogenic factors such as VEGF. Increased
vascular endothelial growth factor-A (VEGF-A) expression has been
associated with poor prognosis in squamous cell carcinoma of the head
and neck.72-81
VEGF has been shown to play an important role in lymph node metas-
tasis through the induction of angiogenesis in nasopharyngeal carcino-
ma.75 In another study, Qian et al.76 has shown that the levels of serum
VEGF were significantly elevated in 65 patients with metastatic
nasopharyngeal carcinoma. A meta-analysis of twelve studies evaluat-
ing VEGF-A expression in 1002 patients with HNSCC,80 showed that
positive VEGF staining was associated with an almost two-fold higher
risk of death at 2 years. Lastly, over-expression of VEGF was seen in
67% of nasopharyngeal cases and the higher expression of VEGF in
EBV positive tumors was related to higher rate of recurrence, nodal
positivity, and lower survival.79 A recent pilot study by Druzgal et al.,81
analyzed the pre- and post-treatment serum levels of cytokines and
angiogenesis factors as markers for outcome in patients with head and
neck cancer. With a median follow-up of 37 months, patients were more
likely to remain disease free when the VEGF level decreased post-treat-
ment versus those who continued to have increased VEGF levels after
treatment. In this study, 7% of the patients had NPC.
Given that high VEGF expression is associated with a worse out-
come, inhibition of this molecule or its receptor has served an attrac-
tive platform in the treatment of head and neck cancers.
In NPC, there are a very few of trials assessing the role of AAT, and
the results are commonly disappointing. In one phase II trial79 seven
patients with recurrent or metastatic NPC were treated with sorafenib;
the median time to treatment progression was 3.2 months, with an
associated OS of 7.7 months. Currently, the RTOG has completed accru-
al to a phase II trial (RTOG 0615), assessing the role of bevacizumab
added to concurrent CRT and adjuvant cisplatin and 5-FU in locally
advanced/advanced NPC.77,81
Conclusions
Based on large number of randomized controlled trials and meta-
analyses, there are sufficient evidences to support CRT should be
adopted as the standard of care for locally advanced NPC, not only in
endemic areas, but also in non-endemic areas. Concomitant CRT has
shown statistically significant improvement in OS and DFS for all his-
tological types of locally advanced NPC, and achieving 5-year OS rates
of about 70% in patients with non-metastatic stage III and IV disease.
Cisplatin-containing regimens were most widely studied and have
been conclusively proven active in this disease. However, the CT regi-
men varied markedly among those trials, and the optimal regimen and
scheduling remains to be determined. Incorporation of newer, less
toxic and more effective anticancer agents such as taxanes, or molec-
ular targeted agents in combined modality regimens are being
assessed in locally advanced NPC to improve the outcomes and to
reduce the related treatment toxicity. Certainly, the treatment strate-
gies for NPC will continue to change and evolve as a better under-
standing is gained of the molecular and immune mechanisms that
drive this disease.
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